Does the media favor ARWR or NTRA?

In the previous week, Natera had 26 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 44 mentions for Natera and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Natera's score of 1.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Natera 32 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor RVMD or ARWR?

In the previous week, Revolution Medicines had 54 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Revolution Medicines' score of 0.86 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BIIB or ARWR?

In the previous week, Biogen had 19 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 37 mentions for Biogen and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Biogen's score of 1.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 27 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ALNY or ARWR?

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Alnylam Pharmaceuticals' score of 1.13 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 21 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BNTX or ARWR?

In the previous week, BioNTech had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 20 mentions for BioNTech and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat BioNTech's score of -0.10 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Arrowhead Pharmaceuticals (ARWR) Competitors

$84.91 -3.68 (-4.15%)

As of 08/28/2026 04:00 PM Eastern

Compare

ARWR vs. NTRA, RVMD, BIIB, ALNY, and BNTX

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? Arrowhead Pharmaceuticals's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arrowhead Pharmaceuticals compare to Natera?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Arrowhead Pharmaceuticals has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A
Natera	$2.31B	20.39	-$208.16M	-$1.36	N/A

In the previous week, Natera had 26 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 44 mentions for Natera and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Natera's score of 1.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Natera	32 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Natera has a net margin of -7.11% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Natera's return on equity of -11.38% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Natera	-7.11%	-11.38%	-7.87%

Arrowhead Pharmaceuticals currently has a consensus price target of $97.33, indicating a potential upside of 14.63%. Natera has a consensus price target of $319.38, indicating a potential downside of 2.11%. Given Arrowhead Pharmaceuticals' higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Natera beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A

Revolution Medicines currently has a consensus target price of $198.89, suggesting a potential downside of 4.32%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, suggesting a potential upside of 14.63%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Revolution Medicines had 54 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Revolution Medicines' score of 0.86 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Biogen had 19 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 37 mentions for Biogen and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Biogen's score of 1.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	27 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biogen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.26	$1.29B	$5.65	38.67
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A

87.9% of Biogen shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biogen has a net margin of 8.32% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Biogen's return on equity of 11.18% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Biogen presently has a consensus target price of $227.79, indicating a potential upside of 4.25%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 14.63%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Biogen beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Alnylam Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.54	$313.75M	$5.38	44.07
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Alnylam Pharmaceuticals presently has a consensus target price of $386.14, indicating a potential upside of 62.86%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 14.63%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Alnylam Pharmaceuticals' score of 1.13 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	21 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

15.5% of BioNTech shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioNTech currently has a consensus target price of $127.81, indicating a potential upside of 25.22%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 14.63%. Given BioNTech's stronger consensus rating and higher possible upside, research analysts plainly believe BioNTech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, BioNTech had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 20 mentions for BioNTech and 18 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat BioNTech's score of -0.10 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Summary

BioNTech beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.96B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-37.74	11.62	273.16	25.42
Price / Sales	14.42	1,314.79	615.35	86.95
Price / Cash	711.14	106.39	76.74	53.00
Price / Book	25.65	16.53	12.98	6.14
Net Income	-$1.63M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-2.53%	-0.31%	0.13%	-0.80%
1 Month Performance	-2.76%	9.80%	7.08%	4.13%
1 Year Performance	285.43%	55.66%	24.67%	15.17%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.5258 of 5 stars	$84.91 -4.2%	$97.33 +14.6%	+285.4%	$11.96B	$829.45M	N/A	400	Positive News
NTRA Natera	2.4928 of 5 stars	$327.72 -1.3%	$319.38 -2.5%	+93.9%	$47.86B	$2.31B	N/A	6,140	Positive News Insider Trade
RVMD Revolution Medicines	2.5137 of 5 stars	$211.58 +1.0%	$167.89 -20.6%	+447.5%	$44.89B	$11.58M	N/A	250	Trending News Analyst Forecast Insider Trade Analyst Revision
BIIB Biogen	3.5917 of 5 stars	$218.12 +0.6%	$227.07 +4.1%	+65.3%	$32.03B	$9.89B	38.61	7,500	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.8779 of 5 stars	$236.01 -0.1%	$386.62 +63.8%	-46.9%	$31.61B	$3.71B	43.87	2,770	News Coverage Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. NTRA, RVMD, BIIB, ALNY, and BNTX

How does Arrowhead Pharmaceuticals compare to Natera?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. NTRA, RVMD, BIIB, ALNY, and BNTX

How does Arrowhead Pharmaceuticals compare to Natera?

Which has higher valuation & earnings, ARWR or NTRA?

Does the media favor ARWR or NTRA?

Do institutionals and insiders hold more shares of ARWR or NTRA?

Which has more risk & volatility, ARWR or NTRA?

Is ARWR or NTRA more profitable?

Do analysts recommend ARWR or NTRA?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Is RVMD or ARWR more profitable?

Which has better valuation and earnings, RVMD or ARWR?

Do analysts rate RVMD or ARWR?

Do institutionals & insiders hold more shares of RVMD or ARWR?

Does the media favor RVMD or ARWR?

Which has more risk & volatility, RVMD or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Does the media refer more to BIIB or ARWR?

Which has preferable valuation and earnings, BIIB or ARWR?

Do institutionals and insiders believe in BIIB or ARWR?

Is BIIB or ARWR more profitable?

Which has more volatility and risk, BIIB or ARWR?

Do analysts prefer BIIB or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Is ALNY or ARWR more profitable?

Which has preferable earnings and valuation, ALNY or ARWR?

Which has more risk and volatility, ALNY or ARWR?

Do analysts prefer ALNY or ARWR?

Does the media favor ALNY or ARWR?

Do insiders & institutionals have more ownership in ALNY or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Is BNTX or ARWR more profitable?

Do insiders and institutionals hold more shares of BNTX or ARWR?

Do analysts recommend BNTX or ARWR?

Does the media refer more to BNTX or ARWR?

Which has higher earnings & valuation, BNTX or ARWR?

Which has more volatility & risk, BNTX or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools